Repatha Cost in Arizona 2026: Price, Insurance, Medicaid, and Compounding Options

What Is Evolocumab and Why Does Cost Matter in Arizona?

Evolocumab (brand name Repatha) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab keeps more LDL receptors on hepatocyte surfaces, which lowers circulating LDL-C by 50 to 60 percent on top of maximally tolerated statin therapy. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering. [1]

The cardiovascular benefit is substantial. In the FOURIER trial (N=27,564), evolocumab 140 mg every two weeks reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization by 15 percent versus placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years. [2] LDL-C fell from a median of 92 mg/dL at baseline to 30 mg/dL at 48 weeks in the evolocumab group. [2]

Despite that evidence, cost remains a real barrier. Arizona has approximately 7.4 million residents as of 2024, and the state's Medicaid program, AHCCCS, does not currently list evolocumab on its preferred drug list. [3] For the roughly 400,000 Arizonans living with familial hypercholesterolemia or established ASCVD who might qualify for PCSK9 inhibitor therapy, understanding every available pricing pathway is clinically relevant. [4]

Repatha List Price in Arizona 2026

The Amgen wholesale acquisition cost for Repatha sits at approximately $580 per month in 2026 for the standard 140 mg autoinjector regimen. That figure applies whether a patient fills at a large chain pharmacy in Phoenix, a community pharmacy in Tucson, or through a specialty mail-order service. [5]

Cash price and list price are not always the same number. GoodRx and similar discount platforms sometimes offer coupons in the $520 to $580 range for Arizona zip codes, but those discounts cannot be combined with insurance or the Amgen copay card. Most patients paying cash in Arizona will realistically face $540 to $580 per monthly fill without additional assistance. The 420 mg once-monthly prefilled cartridge for the on-body injector carries a similar WAC.

Biosimilar PCSK9 inhibitors have entered the U.S. market in limited fashion, but as of mid-2025 none had achieved meaningful formulary penetration in Arizona commercial or Medicaid plans. The FDA's biosimilar approval pathway requires demonstrating no clinically meaningful differences from the reference product. [6] Formulary displacement by biosimilars, if it occurs, could reduce Arizona cash prices substantially within the 2026 to 2028 window.

Arizona Medicaid (AHCCCS) Coverage for Repatha

Arizona Medicaid does not cover Repatha. The Arizona Health Care Cost Containment System, known as AHCCCS, manages Medicaid benefits through contracted managed care organizations. As of the most recent AHCCCS preferred drug list update, evolocumab is not a covered benefit for AHCCCS members, including those with HeFH or established ASCVD. [3]

This matters for a sizable population. AHCCCS covered approximately 2.1 million Arizonans as of fiscal year 2024. [3] Patients with ASCVD or familial hypercholesterolemia who are enrolled in AHCCCS and require PCSK9 inhibition beyond what high-intensity statins and ezetimibe provide are left without a Medicaid pathway to brand-name Repatha.

The American Heart Association and the American College of Cardiology's 2022 guideline on managing blood cholesterol states: "In patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, LOE A)." [7] That Class I recommendation does not, however, compel state Medicaid programs to pay for the drug.

AHCCCS members who meet criteria may still access evolocumab through the Amgen Repatha Assistance Program (see below), through a licensed 503A compounding pharmacy, or through clinical trials. Patients should ask their prescriber to document the medical necessity of PCSK9 inhibition in the chart and to submit a prior authorization request even for Medicaid, because plan formularies can change mid-year and a denial letter is a prerequisite for appeals and external reviews. [8]

Commercial Insurance Prior Authorization in Arizona

Prior authorization is nearly universal for Repatha across Arizona commercial plans. Blue Cross Blue Shield of Arizona, UnitedHealthcare, Aetna, Cigna, and Banner|Aetna all require documentation of statin intolerance or inadequate LDL control before approving evolocumab. [9]

Typical prior authorization criteria in Arizona commercial plans in 2026 include all of the following: a diagnosis of HeFH, HoFH, or established ASCVD; LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH) despite maximally tolerated statin therapy; a trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days unless documented intolerance; and a trial of ezetimibe 10 mg for at least 90 days. [9] Some plans also require bempedoic acid (Nexletol) as an intermediate step.

Once prior authorization is approved, out-of-pocket cost depends on the plan's specialty tier copay or coinsurance. Specialty tier coinsurance of 20 to 33 percent of list price is common, which could mean $116 to $192 per month before the Amgen copay card is applied. The Amgen copay card can reduce that to as little as $0 per month for eligible commercially insured patients. [10]

Step-therapy requirements create delays. A 2020 analysis in the Journal of the American College of Cardiology found that step-therapy barriers for PCSK9 inhibitors were associated with an average 3.5-month delay from initial prescribing to first dispensed dose among commercially insured patients. [11] Arizona law allows patients to request expedited reviews, but the clock still starts with a complete prior authorization submission. Prescribers should submit documentation proactively rather than waiting for a denial.

The Amgen Repatha Copay Card: How It Works in Arizona

The Amgen copay card is available to commercially insured patients who are not enrolled in any federal or state government-funded health program, including Medicare, Medicaid, TRICARE, or any state pharmaceutical assistance program. Arizona AHCCCS members are therefore ineligible. [10]

For eligible patients, the card covers up to $5,600 per calendar year, which is enough to zero out the specialty-tier copay for most Arizona commercial plans that have approved the prior authorization. Enrollment is completed online at Amgen's patient support site or by calling 1-844-REPATHA. [10] The card resets each January 1. Patients who enroll mid-year receive a prorated benefit.

Pharmacies must be enrolled in Amgen's network for the card to process. Most major Arizona retail pharmacies, including CVS, Walgreens, and Fry's/Kroger, participate. Some specialty mail-order pharmacies require a separate enrollment step. If a pharmacy reports a card rejection, the patient should call the number on the back of the card before assuming the benefit is exhausted. [10]

Compounded Evolocumab in Arizona: Legal Status and Cost

Compounded evolocumab from a licensed 503A pharmacy is legal in Arizona. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare patient-specific medications when a licensed prescriber issues a valid prescription. [12] Arizona's Board of Pharmacy licenses 503A pharmacies and enforces compliance with USP <797> sterile compounding standards for injectable preparations. [13]

The cost picture is dramatically different from brand-name Repatha. Compounded evolocumab prepared by a 503A pharmacy in Arizona can approach $0 per month for patients who qualify for income-based assistance programs administered by participating pharmacies, compared with the $580 WAC for the brand. Even without assistance, some 503A pharmacies quote prices in the $99 to $199 per month range for compounded PCSK9 inhibitor formulations.

Clinicians and patients should understand several important distinctions. First, compounded medications are not FDA-approved and have not undergone the same manufacturing quality controls, stability studies, or bioequivalence testing as Repatha. [12] Second, the FDA has not placed evolocumab on its Demonstrably Difficult to Compound (DDC) list, which means 503A compounding of this molecule is not currently prohibited by the agency. Third, the clinical evidence base, including FOURIER [2] and GLAGOV [14], was built exclusively with the brand-name Amgen product. Whether a compounded formulation produces identical pharmacokinetics and the same degree of LDL-C lowering has not been established in a peer-reviewed clinical trial.

The ACC/AHA cholesterol guideline notes that LDL-C response should be confirmed four to twelve weeks after initiating PCSK9 inhibitor therapy and every three to twelve months thereafter. [7] This monitoring requirement is especially relevant for patients on compounded evolocumab, where batch-to-batch variability is a theoretical concern. A repeat fasting lipid panel at eight weeks after the first compounded dose is a reasonable clinical checkpoint.

Prescribers in Arizona who write for compounded evolocumab should document in the medical record the rationale for compounding (typically cost or access), confirm the pharmacy holds a current Arizona Board of Pharmacy 503A license, and establish a monitoring schedule. [13] Patients should inject subcutaneously in the abdomen, thigh, or upper arm, rotating sites, and store the medication at 36 to 46 degrees Fahrenheit.

Telehealth Prescribing of Repatha in Arizona

Arizona permits telehealth prescribing of evolocumab. Following the state's 2019 telehealth expansion and subsequent alignment with federal flexibilities extended after the public health emergency, physicians, nurse practitioners, and physician assistants licensed in Arizona may prescribe controlled and non-controlled medications via synchronous audio-video encounters without a prior in-person visit, provided they establish a valid patient-provider relationship. [15]

For a telehealth evolocumab visit to meet standard of care, the provider should review a recent fasting lipid panel (drawn within the prior 90 days is reasonable), document the patient's cardiovascular history and statin trial, confirm the absence of contraindications, and transmit the prior authorization request to the insurance plan or the compounding pharmacy prescription to the patient's chosen 503A pharmacy. [7]

HealthRX prescribers in Arizona conduct these assessments via HIPAA-compliant video visits. Lab results can be uploaded by the patient or pulled from a connected electronic health record. The prescriber signs the prior authorization documentation and routes it electronically, reducing the time from initial visit to pharmacy processing compared with a traditional in-office workflow.

Amgen Patient Assistance and Other Arizona Discount Programs

Amgen's REPATHA FIRST program offers free brand-name medication to uninsured or underinsured patients who meet income eligibility criteria, typically household income at or below 400 percent of the federal poverty level. [10] Applications are submitted online or through the prescribing provider's office. Processing takes approximately two to four weeks, and approved patients receive Repatha at no charge for up to twelve months, with annual renewal.

The NeedyMeds database lists additional Arizona-specific patient assistance resources for cardiovascular medications. [16] The Arizona Department of Health Services also maintains a pharmaceutical assistance referral list, though evolocumab is not directly administered through any state program as of 2026. [17]

For patients who do not qualify for manufacturer assistance and cannot access a 503A compounding pharmacy, bempedoic acid (Nexletol, 180 mg daily) offers a non-statin LDL-lowering alternative. In the CLEAR Outcomes trial (N=13,970), bempedoic acid reduced LDL-C by 21.1 percent versus placebo and reduced the four-component MACE endpoint by 13 percent (HR 0.87 to 95% CI 0.79 to 0.96, P=0.004) in statin-intolerant patients. [18] Bempedoic acid is substantially less expensive than PCSK9 inhibitors and is covered on most Arizona commercial formularies at tier 2 or 3.

Inclisiran (Leqvio), a small interfering RNA PCSK9 inhibitor dosed twice yearly by a healthcare provider, carries a similar list price to evolocumab but a different coverage trajectory. The ORION-10 trial (N=1,561) showed inclisiran 284 mg SC on day 1, day 90, and every 6 months thereafter reduced LDL-C by 52.3 percent versus placebo at day 510 (P<0.001). [19] Some Arizona commercial plans have added inclisiran to formulary as an alternative to evolocumab when the prior authorization criteria are otherwise equivalent.

Monitoring, Dosing, and Clinical Expectations in Arizona Practice

Evolocumab is dosed as 140 mg subcutaneous injection every two weeks or 420 mg subcutaneous injection once monthly. The two regimens produce equivalent LDL-C lowering. [1] The once-monthly 420 mg dose requires three consecutive 140 mg injections within 30 minutes using the SureClick autoinjector or a single prefilled cartridge with the Pushtronex on-body injector device.

Patients should expect to see maximum LDL-C reduction within four weeks of the first dose. In FOURIER, the mean LDL-C at 48 weeks in the evolocumab group was 30 mg/dL, and 42 percent of patients achieved LDL-C below 25 mg/dL. [2] Patients with baseline LDL-C of 70 to 100 mg/dL on maximally tolerated statin therapy typically reach 35 to 50 mg/dL after starting evolocumab.

The most common adverse effects reported in FOURIER were nasopharyngitis (7.4% evolocumab vs. 7.6% placebo), upper respiratory tract infection, and injection site reactions (2.1% vs. 1.6%). [2] Neurocognitive concerns raised in early post-marketing experience were not confirmed in the EBBINGHAUS cognition substudy of FOURIER (N=1,204), which found no significant difference in cognitive function between evolocumab and placebo groups over a median of 19 months. [20]

Liver function testing and CK monitoring are not routinely required before or during evolocumab therapy based on the FDA label. [1] A repeat fasting lipid panel at eight to twelve weeks after initiation confirms therapeutic response and provides documentation for prior authorization renewal.

Step-by-Step Pathway for Arizona Patients in 2026

Getting from a cardiology or primary care visit to a dispensed dose of evolocumab in Arizona involves specific steps. The prescriber confirms eligibility by reviewing the most recent lipid panel, cardiovascular history, and statin or ezetimibe trial documentation. The prescriber then selects the access pathway most likely to result in rapid dispensing at low cost for that specific patient.

For commercially insured patients with an approved prior authorization, the Amgen copay card route usually yields the lowest out-of-pocket cost. For AHCCCS members or uninsured patients, the REPATHA FIRST program or a licensed 503A compounding pharmacy is the realistic pathway. For patients who are commercially insured but facing a lengthy prior authorization process, a bridge supply through a 503A pharmacy at a lower cost can cover the gap while the insurance appeal proceeds.

The prescriber submits the prior authorization with supporting documentation: lipid panel showing LDL-C at or above the plan's threshold, diagnosis codes for ASCVD or FH (ICD-10 I25.10 for ASCVD, E78.01 for HeFH, E78.02 for HoFH), statin trial documentation including dose and duration, ezetimibe trial documentation, and the clinical rationale for PCSK9 inhibitor initiation. [9] Complete documentation on the first submission reduces the rate of initial denials.

A repeat lipid panel at eight weeks, then annually, serves both the clinical goal of confirming LDL-C response and the administrative goal of supporting prior authorization renewals. Most Arizona commercial plans require annual re-authorization with documentation of ongoing LDL-C response.